Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 287 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Cancer for Phase II Clear all
Withdrawn Phase 2 Interventional

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

NCT03541486
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Ascorbate, Gemcitabine, radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 10, 2026, 5:05 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

NCT01882946
View directory record Official record
Conditions
Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Melanoma
Interventions
DCVax-Direct
Biological
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 10, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT07282912
View directory record Official record
Conditions
Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma, Gallbladder Adenocarcinoma, Intra - and Extrahepatic Cholangiocarcinoma
Interventions
Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

NCT00068575
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Recombinant Interferon Alfa, Cisplatin, Fluorouracil, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

NCT00602602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

NCT02905578
View directory record Official record
Conditions
Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, nab-paclitaxel, Pharmacological ascorbate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

NCT06843551
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
Radiation · Drug
Lead sponsor
Benjamin Spieler
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

NCT01515046
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer
Interventions
Gemcitabine with escalating ascorbic acid
Drug
Lead sponsor
Joseph J. Cullen
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas

NCT00003951
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
exatecan mesylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer

NCT00003332
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cisplatin, gemcitabine hydrochloride, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 10, 2026, 5:05 PM EDT
Withdrawn Phase 2 Interventional

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

NCT02080221
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Fairhaven, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

NCT02578732
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Alanosine in Treating Patients With Cancer

NCT00062283
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
Interventions
L-alanosine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • La Verne, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional

Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

NCT00038701
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
TNP-470
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Surgically Resected Pancreatic Cancer

NCT00255827
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreatic Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 10, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309
View directory record Official record
Conditions
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

NCT00389610
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreas vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

NCT02648282
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

NCT00881621
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Lapatinib and Capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

NCT02950025
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
Interventions
Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 10, 2026, 5:05 PM EDT